Maris 2023:
A takaice dai:
The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell far iya be used to treat epithelial ovarian cancer that has come back or stopped responding to other treatments.
Cikakken Bayani:
Manufofin Farko
To determine the feasibility and safety of anti-MESO CAR-T cells in treating patients with MESO-positive ovarian cancer.
Makasudin Sakandare
To assess the efficacy of anti-MESO CAR-T cells in patients with ovarian cancer.
To determine the in vivo dynamics and persistency of anti-MESO CAR-T cells.
nazarin zane
Nau'in Nazari: Tsangwama (Gwajin Jiyya)
Ƙimar Yin rajista: Mahalarta 20
Rarraba: N/A
Samfurin Sa baki: Ƙungiya Guda Daya
Masking: Babu (Bude Label)
Manufar Farko: Jiyya
Taken Hukuma: Aminci da Tasirin Magungunan ƙwayoyin cuta na MESO-CAR T don Ciwon Ciwon Ciwon Kwai da Refractory
Ƙididdigar Ƙididdigan Fara Karatu: Afrilu 20, 2019
Ƙididdigar Ƙimar Ƙarshen Farko: 20 ga Afrilu, 2022
Ƙididdigar Ƙimar Ƙarshen Nazarin: Afrilu 20, 2023
sharudda
Ka'idodin Hadawa:
18 to 70 Years Old, female; Expected survival > 12 weeks; Clinical performance status of ECOG score 0–2; Patients who have previously been treated with second-line or more lines of standard treatment are not effective (No remission or recurrence after remission); At least one measurable tumor foci according to RECIST standard 1.1 ; Positive Mesothelin expression in tumor tissues; Creatinine ≤ 1.5×ULN; ALT and AST ≤ 3×ULN; Total bilirubin ≤ 2×ULN; Hemoglobin≥90g/L; Absolute counting of neutrophils≥1000uL ; Absolute counting of lymphocytes>0.7×10^9/L; Counting of Platelets≥75000/uL; The venous access required for collection can be established without contraindications for leukocyte collection. I am able to understand and sign the informed consent document.
Ka'idojin keɓewa:
Accompanied by other uncontrolled malignant tumors; Active hepatitis B, hepatitis C, syphilis, HIV infection; Suffering severe cardiovascular or respiratory disease; Any other diseases could affect the outcome of this trial. Any affairs that could affect the safety of the subjects or outcome of this trial Pregnant or lactating women, or patients who plan to be pregnant during or after treatment; There are active or uncontrollable infections (except simple urinary tract infections or upper respiratory tract infections) that require systemic therapy 14 days or 14 days prior to assignment; Patients who are accounted by researchers as not appropriate for this test; Received CAR-T treatment or other gene therapies before assignment; Subject suffering disease affects the understanding of informed consent or compliance with study protocol.
Duba jerin asibitocin da suke yi CAR T-Cell far a kasar Sin.
